Case Name: In re: DISCOVERY LABORATORIES SECURITIES LITIGATION. The Mizla Group (Joseph, Denise, Alan, Erin, Julia Mizla) and Claire Spooner, Appellants
Court: United States Court of Appeals for the Third Circuit
Jurisdiction: United States
Decision Date: 2008-04-29
Citations: 276 F. App'x 154
Docket Number: No. 07-2080
Parties: In re: DISCOVERY LABORATORIES SECURITIES LITIGATION. The Mizla Group (Joseph, Denise, Alan, Erin, Julia Mizla) and Claire Spooner, Appellants.
Judges: 
Reporter: West's Federal Appendix
Volume: 276
Pages: 154–155

Head Matter:
In re: DISCOVERY LABORATORIES SECURITIES LITIGATION. The Mizla Group (Joseph, Denise, Alan, Erin, Julia Mizla) and Claire Spooner, Appellants.
No. 07-2080.
United States Court of Appeals, Third Circuit.
Argued March 25, 2008.
Filed: April 29, 2008.
James R. Malone, Jr., Esq. [Argued], Chimicles & Tikellis, Haverford, PA, for Appellants The Mizla Group.
Carol A. Mager, Esq., Mager & Gold-stein, Philadelphia, PA, for Appellant Claire Spooner.
Robert L. Hickok, Esq. [Argued], Christopher J. Huber, Esq., Gay P. Rainville, Esq., Pepper Hamilton, Philadelphia, PA, for Appellees.
Before: McKEE, RENDELL and TASHIMA , Circuit Judges.
Honorable A. Wallace Tashima, Senior Judge of the United States Court of Appeals for the Ninth Circuit, sitting by designation.

Opinion:
OPINION OF THE COURT
RENDELL, Circuit Judge.
Plaintiffs, the Mizla Group and Clame Spooner, appeal the dismissal of their Second Amended Complaint ("the Complaint") in a securities class action. In the Complaint, they alleged violations of Section 10(b) of the Securities Exchange Act of 1934, 15 U.S.C. § 78¡j(b), and Rule 10b-5 promulgated under the Act, 17 CFR § 240.10b-5, by defendants, Discovery Laboratories, Inc. ("Discovery"), Robert Capetola, President and Chief Executive Officer of Discovery, and Christopher Schaber, former Chief Operating Officer of Discovery. The District Court considered the claims in the Complaint in a lengthy opinion and ultimately dismissed each claim for failure to sufficiently plead materiality and/or scienter under the heightened pleading standards of the Private Securities Litigation Reform Act. The plaintiffs appeal the dismissal of the majority of their claims, but have abandoned or waived others.
We find the District Court's opinion well-reasoned and do not find that any of the issues before us constitutes grounds for disturbing or varying from its analysis. Accordingly, we will affirm the dismissal of the complaint for the reasons set forth therein.
. In particular, we note that appellants appeal the dismissal of their allegations relating to statements made regarding the likelihood of approval by the European Medicines Evaluation Agency only on the basis of materiality. The District Court, however, dismissed those allegations based on insufficient pleading of scienter as well, and appellants do not challenge that determination on appeal. Thus, a ruling in their favor on the materiality issue would be unavailing.